Osteofibrous Dysplasia and Adamantinoma

Alessandra F Nascimento; Scott E Kilpatrick; John D Reith

doi:10.1016/j.path.2021.06.012

Osteofibrous Dysplasia and Adamantinoma

Surg Pathol Clin. 2021 Dec;14(4):723-735. doi: 10.1016/j.path.2021.06.012. Epub 2021 Oct 7.

Authors

Alessandra F Nascimento¹, Scott E Kilpatrick², John D Reith³

Affiliations

¹ Department of Pathology, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
² Department of Pathology, L25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
³ Department of Pathology, L25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: reithj2@ccf.org.

PMID: 34742490
DOI: 10.1016/j.path.2021.06.012

Abstract

For decades, the diagnosis, treatment, and even pathogenesis of the osteofibrous dysplasia/osteofibrous dysplasia-like adamantinoma/classic adamantinoma spectrum of neoplasms have been controversial. Herein, we discuss and illustrate the radiographic and histologic spectrum, differential diagnoses, unifying chromosomal and molecular abnormalities, and current controversies and treatment recommendations for each entity.

Keywords: Adamantinoma; Dedifferentiated adamantinoma; OFD-like adamantinoma; Osteofibrous dysplasia.

Publication types

Review

MeSH terms

Adamantinoma* / diagnosis
Bone Diseases, Developmental* / diagnosis
Bone Diseases, Developmental* / genetics
Bone Neoplasms* / diagnosis
Diagnosis, Differential
Humans

Supplementary concepts

Osteofibrous Dysplasia